Weekly docetaxel is safe and effective in the treatment of advanced-stage acquired immunodeficiency syndrome-related Kaposi sarcoma

Cancer

Volumn 103, Issue 2, 2005, Pages 417-421

  Soon, Thye Lim ^a,b   Tupule, Anil ^a   Espina, Byron M ^a   Levine, Alexandra M ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Antitumor activity; Docetaxel; Kaposi sarcoma; Myelosuppression

Indexed keywords

DOCETAXEL;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER REGRESSION; CELLULITIS; CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FOLLOW UP; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; INSOMNIA; KAPOSI SARCOMA; MALE; MUCOSA INFLAMMATION; MYALGIA; NAIL BED; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS; THROMBOCYTOPENIA; VOMITING;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM STAGING; RISK ASSESSMENT; SARCOMA, KAPOSI; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 12344326501     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20780     Document Type: Article

References (15)

1. Northfelt DW, Dezube BJ, Thommes JA, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol. 1998;16:2445-2451.
2. Stewart S, Jablonowski H, Goebel FD, et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related KS. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol. 1998;16:683-691.
3. Gill PS, Wernz J, Scadden DT, et al. Randomized phase III study of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related KS. J Clin Oncol. 1996;14:2353-2364.
4. Gill PS, Tulpule A, Espina BM, et al. Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma. J Clin Oncol. 1999;6:1876-1883.
5. Boue F, Zaikas G, Lancar R, et al. Activity of Taxotere (docetaxel) as therapy for pretreated HIV-associated Kaposi's sarcoma (KS): an ANRS trial [abstract 182],. Proc Am Soc Clin Oncol 1998;17:47a.
6. Hainsworth JD, Burris HA 3rd, Yardley DA. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol. 2001;15:3500-3505.
7. Krown SE, Metroka C, Wernz JC: Kaposi's sarcoma and the acquired immunodeficiency syndrome: a proposal for a uniform evaluation, response and staging criteria. J Clin Oncol. 1989;7:1201-1207.
8. Verschraegen CF, Sittisomwong T, Kudelka AP, et al. Docetaxel for patients with paclitaxel-resistant mullerian carcinoma. J Clin Oncol. 2000;14:2733-2739.
9. Valero V, Jones SE, Von Hoff DD, et al: A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol. 1998;16:3362-3368.
10. Lebbe C, Blum L, Pellet C, et al. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma. AIDS. 1998;12:F45-F49.
11. Diz Dios P, Ocampo Hermida A, Miralles Alvarez C, et al. Regression of AIDS-related Kaposi's sarcoma following ritonavir therapy. Oral Oncol. 1998;34:236-238.
12. Minisini AM, Tosti A, Sobrero AF, et al. Taxane-induced nail changes: incidence, clinical presentation and outcome. Ann Oncol. 2003;2:333-337.
13. Ledergerber B, Telenti A, Egger M. Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study. Swiss HIV Cohort Study. BMJ. 1999;319:23-24.
14. Herida M, Mary-Krause M, Kaphan R, et al. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst. 2000;92:1823-1830.
15. Jones JL, Hanson DL, Dworkin MS, et al. Incidence and trends in Kaposi's sarcoma in the era of effective antiretroviral therapy. J Acquir Immune Defic Syndr. 2000;3:270-274.